97 related articles for article (PubMed ID: 7889493)
1. Elevated serum Lp(a) levels in the early and advanced stages of breast cancer.
Kökoğlu E; Karaarslan I; Karaarslan HM; Baloğlu H
Cancer Biochem Biophys; 1994 Sep; 14(2):133-6. PubMed ID: 7889493
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
3. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum arginase activity levels in patients with breast cancer.
Polat MF; Taysi S; Polat S; Böyük A; Bakan E
Surg Today; 2003; 33(9):655-61. PubMed ID: 12928840
[TBL] [Abstract][Full Text] [Related]
5. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L
Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728
[TBL] [Abstract][Full Text] [Related]
6. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease.
Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS
Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407
[TBL] [Abstract][Full Text] [Related]
7. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study.
Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D
Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994
[TBL] [Abstract][Full Text] [Related]
9. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
10. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
[TBL] [Abstract][Full Text] [Related]
12. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
13. [Proteome analysis for identification of tumor-associated biomarkers in breast cancer].
Wang X; Liang WJ; Zhu ZY; Yang MT; Zeng YX
Ai Zheng; 2004 Nov; 23(11 Suppl):1577-81. PubMed ID: 15566683
[TBL] [Abstract][Full Text] [Related]
14. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
15. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
17. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
18. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status.
Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y
Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978
[TBL] [Abstract][Full Text] [Related]
19. Elevation of serum riboflavin carrier protein in breast cancer.
Rao PN; Levine E; Myers MO; Prakash V; Watson J; Stolier A; Kopicko JJ; Kissinger P; Raj SG; Raj MH
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):985-90. PubMed ID: 10566553
[TBL] [Abstract][Full Text] [Related]
20. Prediction of breast tumor progression by integrity of free circulating DNA in serum.
Umetani N; Giuliano AE; Hiramatsu SH; Amersi F; Nakagawa T; Martino S; Hoon DS
J Clin Oncol; 2006 Sep; 24(26):4270-6. PubMed ID: 16963729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
